You need JavaScript to view this

Anti-tumor effects of Egr-IFN gamma gene therapy combined with {sup 125}I-UdR radionuclide therapy

Journal Article:

Abstract

Objective: To explore the anti-tumor effects of Egr-IFNgamma gene therapy combined with {sup 125}I-UdR radionuclide therapy in mice bearing H22 hepatocarcinoma and its mechanism. Methods: The recombinant plasmid pcDNAEgr-IFNgamma mixed with liposome was injected into tumor. 48 h later, 370 kBq {sup 125}I-UdR was injected into tumor. The tumor growth rates at different times were observed. After 3 d gene-radionuclide therapy, the concentration of IFNgamma in cytoplasm of H22 cells and cytotoxic activities of splenic CTL of the mice in different groups were examined. Results: The tumor growth rates of pcDNAEgr-IFNgamma + {sup 125}I-UdR group were obviously lower than those of control group, {sup 125}I-UdR group and pcDNAEgr-1 + {sup 125}I-UdR group 6-15 d after gene-radionuclide therapy. IFNgamma protein was found in cytoplasm of H22 cells in pcDNAEgr-IFNgamma + {sup 125}I-UdR group after 3 d gene-radionuclide therapy. Cytotoxic activity of splenic CTL in pcDNAEgr-IFNgamma + {sup 125}I-UdR group was significantly higher than that in the other groups (P<0.01). Conclusions: The anti-tumor effects in vivo of pcDNAEgr-IFNgamma gene therapy combined with {sup 125}I-UdR radionuclide therapy are better than those of {sup 125}I-UdR therapy. (authors)
Authors:
Jingguo, Zhao; [1]  Yanjun, Ni; Xiangfu, Song; Yanyi, Li; Wei, Yang; Ting, Sun; Qingjie, Ma; Fengtong, Gao
  1. No.403 Hospital of PLA, Dalian (China)
Publication Date:
Dec 15, 2008
Product Type:
Journal Article
Resource Relation:
Journal Name: Chinese Journal of Radiological Medicine and Protection; Journal Volume: 28; Journal Issue: 6; Other Information: 1 fig., 1 tab., 8 refs.
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; COMBINED THERAPY; CYTOPLASM; GENE THERAPY; GENES; GROWTH; HEPATOMAS; IN VIVO; INHIBITION; IODINE 125; MICE; NEOPLASMS; PROTEINS; RADIOPHARMACEUTICALS; RADIOTHERAPY; TUMOR CELLS; URIDINE; ANIMAL CELLS; ANIMALS; AZINES; BETA DECAY RADIOISOTOPES; CARCINOMAS; CELL CONSTITUENTS; DAYS LIVING RADIOISOTOPES; DISEASES; DRUGS; ELECTRON CAPTURE RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HYDROXY COMPOUNDS; INTERMEDIATE MASS NUCLEI; INTERNAL CONVERSION RADIOISOTOPES; IODINE ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; MAMMALS; MATERIALS; MEDICINE; NUCLEAR MEDICINE; NUCLEI; NUCLEOSIDES; NUCLEOTIDES; ODD-EVEN NUCLEI; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; PYRIMIDINES; RADIOACTIVE MATERIALS; RADIOISOTOPES; RADIOLOGY; RIBOSIDES; RODENTS; THERAPY; URACILS; VERTEBRATES
OSTI ID:
21361150
Country of Origin:
China
Language:
Chinese
Other Identifying Numbers:
Journal ID: ISSN 0254-5098; TRN: CN1001982095504
Submitting Site:
INIS
Size:
page(s) 606-608
Announcement Date:
Dec 04, 2010

Journal Article:

Citation Formats

Jingguo, Zhao, Yanjun, Ni, Xiangfu, Song, Yanyi, Li, Wei, Yang, Ting, Sun, Qingjie, Ma, and Fengtong, Gao. Anti-tumor effects of Egr-IFN gamma gene therapy combined with {sup 125}I-UdR radionuclide therapy. China: N. p., 2008. Web.
Jingguo, Zhao, Yanjun, Ni, Xiangfu, Song, Yanyi, Li, Wei, Yang, Ting, Sun, Qingjie, Ma, & Fengtong, Gao. Anti-tumor effects of Egr-IFN gamma gene therapy combined with {sup 125}I-UdR radionuclide therapy. China.
Jingguo, Zhao, Yanjun, Ni, Xiangfu, Song, Yanyi, Li, Wei, Yang, Ting, Sun, Qingjie, Ma, and Fengtong, Gao. 2008. "Anti-tumor effects of Egr-IFN gamma gene therapy combined with {sup 125}I-UdR radionuclide therapy." China.
@misc{etde_21361150,
title = {Anti-tumor effects of Egr-IFN gamma gene therapy combined with {sup 125}I-UdR radionuclide therapy}
author = {Jingguo, Zhao, Yanjun, Ni, Xiangfu, Song, Yanyi, Li, Wei, Yang, Ting, Sun, Qingjie, Ma, and Fengtong, Gao}
abstractNote = {Objective: To explore the anti-tumor effects of Egr-IFNgamma gene therapy combined with {sup 125}I-UdR radionuclide therapy in mice bearing H22 hepatocarcinoma and its mechanism. Methods: The recombinant plasmid pcDNAEgr-IFNgamma mixed with liposome was injected into tumor. 48 h later, 370 kBq {sup 125}I-UdR was injected into tumor. The tumor growth rates at different times were observed. After 3 d gene-radionuclide therapy, the concentration of IFNgamma in cytoplasm of H22 cells and cytotoxic activities of splenic CTL of the mice in different groups were examined. Results: The tumor growth rates of pcDNAEgr-IFNgamma + {sup 125}I-UdR group were obviously lower than those of control group, {sup 125}I-UdR group and pcDNAEgr-1 + {sup 125}I-UdR group 6-15 d after gene-radionuclide therapy. IFNgamma protein was found in cytoplasm of H22 cells in pcDNAEgr-IFNgamma + {sup 125}I-UdR group after 3 d gene-radionuclide therapy. Cytotoxic activity of splenic CTL in pcDNAEgr-IFNgamma + {sup 125}I-UdR group was significantly higher than that in the other groups (P<0.01). Conclusions: The anti-tumor effects in vivo of pcDNAEgr-IFNgamma gene therapy combined with {sup 125}I-UdR radionuclide therapy are better than those of {sup 125}I-UdR therapy. (authors)}
journal = {Chinese Journal of Radiological Medicine and Protection}
issue = {6}
volume = {28}
place = {China}
year = {2008}
month = {Dec}
}